|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010346,
umls-concept:C0087111,
umls-concept:C0337810,
umls-concept:C0439743,
umls-concept:C0666743,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2603343,
umls-concept:C2698872,
umls-concept:C2911692
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2005-7-5
|
|
pubmed:abstractText |
Almost 20% of patients with active Crohn's disease are refractory to conventional therapy. Infliximab is a treatment of proven efficacy in this group of patients and it is not clear which variables predict a good response. AIMS.: To evaluate the role of infliximab looking at the predictors of response in a large series of patients with Crohn's disease.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1590-8658
|
|
pubmed:author |
pubmed-author:AngelucciEE,
pubmed-author:BenazzatoLL,
pubmed-author:BianconeLL,
pubmed-author:BosseJJ,
pubmed-author:CassinottiAA,
pubmed-author:CastiglioneFF,
pubmed-author:ColomboEE,
pubmed-author:CosintinoRR,
pubmed-author:CottoneMM,
pubmed-author:GeremiaAA,
pubmed-author:Italian Multicentric Study Group on Infliximab,
pubmed-author:KohnAA,
pubmed-author:LavagnaAA,
pubmed-author:MeucciGG,
pubmed-author:MocciaroFF,
pubmed-author:MorselliCC,
pubmed-author:OrlandoAA,
pubmed-author:PapoYY,
pubmed-author:RieglerGG,
pubmed-author:RispoAA,
pubmed-author:RizzelloFF,
pubmed-author:ScimecaDD,
pubmed-author:SostegniRR,
pubmed-author:ViscidoAA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
37
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
577-83
|
|
pubmed:meshHeading |
pubmed-meshheading:15886081-Adult,
pubmed-meshheading:15886081-Antibodies, Monoclonal,
pubmed-meshheading:15886081-Crohn Disease,
pubmed-meshheading:15886081-Dose-Response Relationship, Drug,
pubmed-meshheading:15886081-Female,
pubmed-meshheading:15886081-Fistula,
pubmed-meshheading:15886081-Gastrointestinal Agents,
pubmed-meshheading:15886081-Humans,
pubmed-meshheading:15886081-Italy,
pubmed-meshheading:15886081-Male,
pubmed-meshheading:15886081-Multivariate Analysis,
pubmed-meshheading:15886081-Remission Induction,
pubmed-meshheading:15886081-Smoking
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
|
|
pubmed:affiliation |
Department of Internal Medicine, 'V. Cervello' Hospital, Via Trabucco 180, Palermo 90146, Italy. ambrogiorlando@tiscalinet.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|
